Literature DB >> 23247865

Gene expression levels of human shelterin complex and shelterin-associated factors regulated by the topoisomerase II inhibitors doxorubicin and etoposide in human cultured cells.

Masahiro Kato1, Masahiro Nakayama, Minako Agata, Kenichi Yoshida.   

Abstract

Human telomerase reverse transcriptase (hTERT) is responsible for telomere elongation, and its activity is strongly related to the expression level of the hTERT gene; however, the transcriptional regulation of telomeric genes, which play a central role in telomere maintenance and protection by facilitating replication and regulating telomerase access, is poorly understood. In this study, we aimed to reveal the changes in the mRNA expression of six components of the shelterin complex and three shelterin complex-associated factors in topoisomerase II inhibitor-treated human cultured cells. Using a quantitative gene expression analysis, we found that a reduction in telomeric repeat-binding factor 1 (TRF1), protection of telomeres (POT1), and TRF1-interacting ankyrin-related ADP-ribose polymerase 1 (TNKS1) mRNAs was observed in etoposide- and doxorubicin-treated HeLa and U-2 OS cells, while an increased TRF2-interacting telomeric protein (RAP1) mRNA level was observed in U-2 OS cells. Furthermore, doxorubicin suppressed TRF1 and POT1 mRNAs in both Saos-2 and WI-38 cells and increased RAP1 mRNA in WI-38 cells. In agreement with the results obtained in the quantitative gene expression analysis in U-2 OS cells, the topoisomerase II inhibitors negatively and positively regulated the POT1 and RAP1 gene promoters, respectively. Taken together, these results suggest the successful identification of unique topoisomerase II inhibitor-inducible telomeric genes and provide mechanistic insight into the regulation of telomeric gene expression by chemotherapeutic agents.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23247865     DOI: 10.1007/s13277-012-0600-3

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  71 in total

Review 1.  Telomerase and cancer: revisiting the telomere hypothesis.

Authors:  C Autexier; C W Greider
Journal:  Trends Biochem Sci       Date:  1996-10       Impact factor: 13.807

2.  Anthracyclines disrupt telomere maintenance by telomerase through inducing PinX1 ubiquitination and degradation.

Authors:  B Zhang; D Qian; H-H Ma; R Jin; P-X Yang; M-Y Cai; Y-H Liu; Y-J Liao; H-X Deng; S-J Mai; H Zhang; Y-X Zeng; M C Lin; H-F Kung; D Xie; J-J Huang
Journal:  Oncogene       Date:  2011-06-06       Impact factor: 9.867

3.  Tankyrase, a positive regulator of telomere elongation, is over expressed in human breast cancer.

Authors:  Stefania Gelmini; Melissa Poggesi; Vito Distante; Simonetta Bianchi; Lisa Simi; Michaela Luconi; Claudia Casini Raggi; Luigi Cataliotti; Mario Pazzagli; Claudio Orlando
Journal:  Cancer Lett       Date:  2004-12-08       Impact factor: 8.679

Review 4.  Alternative lengthening of telomeres in mammalian cells.

Authors:  Jeremy D Henson; Axel A Neumann; Thomas R Yeager; Roger R Reddel
Journal:  Oncogene       Date:  2002-01-21       Impact factor: 9.867

Review 5.  Telomeres: protecting chromosomes against genome instability.

Authors:  Roderick J O'Sullivan; Jan Karlseder
Journal:  Nat Rev Mol Cell Biol       Date:  2010-02-03       Impact factor: 94.444

Review 6.  On the road to immortality: hTERT upregulation in cancer cells.

Authors:  Ralf Janknecht
Journal:  FEBS Lett       Date:  2004-04-23       Impact factor: 4.124

7.  Opposing regulatory roles of E2F in human telomerase reverse transcriptase (hTERT) gene expression in human tumor and normal somatic cells.

Authors:  Jaejoon Won; Jeongbin Yim; Tae Kook Kim
Journal:  FASEB J       Date:  2002-10-04       Impact factor: 5.191

Review 8.  Telomerase: a target for cancer therapeutics.

Authors:  Jerry W Shay; Woodring E Wright
Journal:  Cancer Cell       Date:  2002-10       Impact factor: 31.743

9.  The POT1-TPP1 telomere complex is a telomerase processivity factor.

Authors:  Feng Wang; Elaine R Podell; Arthur J Zaug; Yuting Yang; Paul Baciu; Thomas R Cech; Ming Lei
Journal:  Nature       Date:  2007-01-21       Impact factor: 69.504

10.  Lack of TRF2 in ALT cells causes PML-dependent p53 activation and loss of telomeric DNA.

Authors:  Martina Stagno D'Alcontres; Aaron Mendez-Bermudez; Jennifer L Foxon; Nicola J Royle; Paolo Salomoni
Journal:  J Cell Biol       Date:  2007-12-03       Impact factor: 10.539

View more
  3 in total

1.  Rap1 is indispensable for TRF2 function in etoposide-induced DNA damage response in gastric cancer cell line.

Authors:  X Li; W Liu; H Wang; L Yang; Y Li; H Wen; H Ning; J Wang; L Zhang; J Li; D Fan
Journal:  Oncogenesis       Date:  2015-03-30       Impact factor: 7.485

Review 2.  Therapeutic Targeting of Telomerase.

Authors:  Kathrin Jäger; Michael Walter
Journal:  Genes (Basel)       Date:  2016-07-21       Impact factor: 4.096

3.  Rap1 regulates hematopoietic stem cell survival and affects oncogenesis and response to chemotherapy.

Authors:  Ekta Khattar; Kyaw Ze Ya Maung; Chen Li Chew; Arkasubhra Ghosh; Michelle Meng Huang Mok; Pei Lee; Jun Zhang; Wei Hong Jeff Chor; Gökhan Cildir; Chelsia Qiuxia Wang; Nur Khairiah Mohd-Ismail; Desmond Wai Loon Chin; Soo Chin Lee; Henry Yang; Yong-Jae Shin; Do-Hyun Nam; Liming Chen; Alan Prem Kumar; Lih Wen Deng; Masahito Ikawa; Jayantha Gunaratne; Motomi Osato; Vinay Tergaonkar
Journal:  Nat Commun       Date:  2019-12-13       Impact factor: 14.919

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.